Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $33.0 million.

  • Amicus Therapeutics' Net Cash Flow rose 1204.1% to $33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$59.7 million, marking a year-over-year decrease of 22418.51%. This contributed to the annual value of -$29.3 million for FY2024, which is 13235.52% down from last year.
  • Amicus Therapeutics' Net Cash Flow amounted to $33.0 million in Q3 2025, which was up 1204.1% from -$32.7 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Net Cash Flow peaked at $212.0 million during Q3 2021, and registered a low of -$146.9 million during Q4 2022.
  • Moreover, its 5-year median value for Net Cash Flow was -$143000.0 (2024), whereas its average is $1.7 million.
  • In the last 5 years, Amicus Therapeutics' Net Cash Flow skyrocketed by 41731.55% in 2023 and then crashed by 2276993.01% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Net Cash Flow (Quarter) stood at -$138.7 million in 2021, then fell by 5.92% to -$146.9 million in 2022, then soared by 91.64% to -$12.3 million in 2023, then crashed by 88.88% to -$23.2 million in 2024, then surged by 242.35% to $33.0 million in 2025.
  • Its last three reported values are $33.0 million in Q3 2025, -$32.7 million for Q2 2025, and -$36.8 million during Q1 2025.